I-Mab Asset Resilience Ratio
I-Mab asset resilience ratio. I-Mab (IMAB) has an Asset Resilience Ratio of 0.08% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of I-Mab to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of I-Mab (2017–2024)
Asset resilience ratio of I-Mab from 2017 to 2024. This chart shows how I-Mab's Asset Resilience Ratio has changed over time. Read I-Mab debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down I-Mab's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IMAB current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $210.00K | 0.08% |
| Total Liquid Assets | $210.00K | 0.08% |
Asset Resilience Insights
- Limited Liquidity: I-Mab maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
I-Mab Industry Peers by Asset Resilience Ratio
Compare I-Mab's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
I-Mab Asset Resilience Ratio by Year (2017–2024)
I-Mab asset resilience ratio by year from 2017 to 2024. The table below shows the annual Asset Resilience Ratio data for I-Mab.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.43% | $105.14 Million | $212.68 Million | +48.66pp |
| 2023-12-31 | 0.77% | $20.22 Million | $2.61 Billion | -5.01pp |
| 2022-12-31 | 5.78% | $235.43 Million | $4.07 Billion | -7.60pp |
| 2021-12-31 | 13.38% | $753.16 Million | $5.63 Billion | +12.88pp |
| 2020-12-31 | 0.50% | $31.53 Million | $6.33 Billion | -1.34pp |
| 2019-12-31 | 1.84% | $32.00 Million | $1.74 Billion | -8.93pp |
| 2018-12-31 | 10.77% | $255.96 Million | $2.38 Billion | -15.19pp |
| 2017-12-31 | 25.97% | $266.25 Million | $1.03 Billion | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more